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Perivascular epithelioid cell tumors (PEComas) are very
rare mesenchymal tumors, characterized by the presence of
perivascular epithelioid cells. Despite their often benign
nature, malignant variants with a locally aggressive growth
pattern and even distant metastases are known. We
describe two cases of malignant PEComas. The first patient
had an extensive peritoneal spread and a history of multiple
resections, and received the mechanistic target of
rapamycin inhibitor sirolimus in a postoperative setting as
maintenance therapy. The second patient presented with
locally advanced disease in the iliac fossa and was treated
with sirolimus in a neoadjuvant setting and achieved
complete remission. Both patients have been under
treatment for 18 and 52 months, respectively, and are
currently in complete remission. These two cases indicate
that mechanistic target of rapamycin inhibition for
malignant PEComas could be a safe and successful
treatment strategy in a neoadjuvant setting with an
acceptable toxicity profile. Anti-Cancer Drugs 27:254–258
Copyright © 2016 Wolters Kluwer Health, Inc. All rights
reserved.
Anti-Cancer Drugs 2016, 27:254–258
Keywords: neoadjuvant therapy, perivascular epithelioid cell neoplasms,
sirolimus
Departments of aInternal Medicine III, bGeneral, Visceral, Transplantation, Vascular,
and Thoracic Surgery, cOrthopaedic Surgery, Orthopaedic Oncology, dClinical
Radiology, eInstitute of Pathology, fCenter for Bone and Soft Tissue Sarcoma
(SarKUM) and gComprehensive Cancer Center, Ludwig-Maximilians-University of
Munich, Munich, Germany
Correspondence to Lars H. Lindner, MD, Department of Internal Medicine III
University of Munich – Campus Grosshadern, Ludwig-Maximilians-University,
Marchioninistr. 15, 81377 Munich, Germany
Tel: + 49 89 4400 74768; fax: + 49 89 4400 74776;
e-mail: lars.lindner@med.uni-muenchen.de
Received 6 October 2015 Revised form accepted 5 November 2015
Introduction
Sarcomas represent a very heterogeneous group of tumors
of mesenchymal origin with variable malignant potential.
Perivascular epithelioid cell tumors (PEComas) encom-
pass a very rare subgroup and not a specific entity, rather a
whole tumor family including angiomyolipomas, lym-
phangiomyomatosis of the lung, and the clear cell ‘sugar’
tumor of the lung or extrapulmonary sites. Histologically,
they all have one similarity: the presence of perivascular
epithelioid cells. These cells have an epithelioid appear-
ance without a known normal counterpart, usually located
adjacent to blood vessels [1]. Immunohistochemically,
myogenic (actin, vimentin, less common desmin) as well
as melanocytic markers (HMB45, Melan A, S100) are
often expressed [2].
Angiomyolipomas of the kidney represent the most com-
mon of the PEComas. In their sporadic form, detected
most often as a benign solitary incidentaloma, there is
usually no need for therapy, but surgical treatment may be
required to prevent complications such as hemorrhage [3].
Ten percent of the tumors are associated with the
tuberous sclerosis complex (TSC), an autosomal domi-
nant inherited disease, characterized by the development
of a variety of benign tumors in multiple organs,
including the brain, heart, skin, eyes, kidney, lung, and
liver, skin lesions, seizures, and learning disability. The
associated angiomyolipomas tend to be larger, more
aggressive, and often multifocal; thus, renal failure, local
invasive growth, and even metastases are possible con-
sequences [4].
Lymphangioleiomyomatosis is a benign but progressive
disease of the lung in premenopausal women, often
presenting clinically with dyspnea, pleural effusion,
pneumothorax, and a slowly progressive pulmonary fail-
ure. It can be associated with the TSC, but most cases are
sporadic without germline mutations [5].
Despite their mostly benign behavior, PEComas with
locally aggressive growth as well as cases with distant
metastases, most commonly located in the lungs, are
known. Malignant PEComas are usually not associated
with TSC. This spindle and epithelioid cell malignancy
typically arises at gynecological sites, the gastrointestinal
tract, in the retroperitoneal space, or in soft tissue. Firm
criteria to make the diagnosis of a PEComa with malig-
nant potential are not well established. However, Folpe
and Kwiatkowski [6] describe a tumor size more than
50 mm, a mitotic index of more than 1 per 50 high-power
fields, infiltrative growth, marked hypercellularity with
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pleomorphism, and nuclear atypia to be associated with
high risk for local recurrence and metastasis.
As the activation of the mechanistic target of rapamycin
(mTOR) pathway seems to play a role in the pathogen-
esis, sirolimus as a selective inhibitor of the mTOR
complex is a possible approach as a targeted therapy.
According to Bissler et al. [7], who observed a significant
tumor volume reduction in patients with malignant
angiomyolipomas associated with TSC treated with sir-
olimus, and Wagner et al. [8], who published a case series
of three patients with malignant PEComa successfully
treated with sirolimus, we decided to treat a patient with
recurrent peritoneal metastasis and a patient with locally
advanced malignant PEComa with sirolimus.
Case reports
Case 1
A 26-year-old woman was first referred to a local clinic in
2001 with localized abdominal pain. A tumor associated
with the transverse colon was diagnosed and resected.
The tumor was examined by a local pathologist and the
diagnosis of a benign mesenchymal tumor was made.
Seven years later, in 2008, another tumor associated with
her greater omentum was detected during a routine
gynecological visit. Following resection, the pathological
examination showed a spindle cell and epithelioid cell
mesenchymal tumor with an immunohistological strong
positivity for CD 117, classified as a gastrointestinal
stromal tumor (GIST). An adjuvant therapy with imatinib
over 1 year was administered.
In 2010, a computed tomographic (CT) scan indicated
multiple tumor nodules disseminated in the abdominal
cavity including the pelvis, associated with the bladder
and both ovaries. All visible tumor tissue was macro-
scopically resected and a diagnosis of a relapsed GIST
was made by the local pathologist. The tumor tissue
showed the same features as the tumor from 2008, but
the Ki-67 proliferative index was now increased to 30%
compared with 2–3% 2 years before.
In 2011, another recurrence with a tumor associated with
the right ovary was found. Again, a laparotomy with tumor
resection was performed. This time, an extended immu-
nohistological examination by a reference pathologist
followed. The tumor tissue showed a malignant spindle
and epithelioid cell neoplasm with high mitotic activity
(54/50 high-power fields) this time also, and 10% necrosis
(Fig. 1). However, no GIST marker could be found (CD
117, DOG-1, and CD 34 all negative). Focal positivity for
actin and a strong continuous positivity for HMB45 was
present. Together with negativity for S100, desmin,
pancytokeratin, EMA, CD 56, CD 57, CD 10, inhibin,
and WT1, the diagnosis of an unusual PEComa was made
and was confirmed by a second pathologist. The tumor
was classified as malignant because of local necrosis,
tumor size, high mitotic activity, and multiple relapses in
the past.
Six months later, another recurrence was found on a
follow-up PET scan in the lower right pelvis (Fig. 2a).
Distant metastases were excluded. The patient was
referred to the Sarcoma Center of Ludwig-Maximilian
University of Munich (SarKUM). In the interdisciplinary
sarcoma conference, the case was discussed and deemed
resectable. However, in the context of the patient’s his-
tory, we considered the risk of another relapse as very
high. We decided to commence with sirolimus as a
neoadjuvant treatment approach on the basis of previous
case reports with successful treatment of malignant
PEComas with mTOR inhibition.
The therapy was well tolerated, without relevant side
effects. Sirolimus plasma concentration was measured
regularly and found to be always within the therapeutic
window, defined as 10–15 μg/l as suggested by Bissler
et al. [7].
During treatment, we performed a CT scan every
3 months. The first scan indicated a progressive central
necrosis and after 6 months of therapy, a partial remission
was achieved (Fig. 2b). An extended surgery followed
and the main tumor as well as some small peritoneal
nodules were resected. Histologically, the diagnosis of a
malignant PEComa was confirmed by our institute of
pathology. The resection was classified as marginal. On
the basis of the intraoperative situs with the detection of
a peritoneal sarcomatosis, we decided to continue the
treatment with sirolimus. To date, 3 years after the last
resection, the patient remains stable without macro-
scopically detectable tumor (Fig. 2c) and is still under-
going therapy with sirolimus, which is well tolerated.
Case 2
A 49-year-old woman presented with local pressure in the
right groin. A CT scan indicated a 10× 4× 3 cm mass in
the right iliac fossa (Fig. 3a), as well as enlarged para-
aortic and parailiac lymph nodes. A first ultrasound-
guided biopsy showed only unspecific altered and
necrotic tissue; a second biopsy indicated a mesenchymal
epithelioid cell neoplasm with uniform small nuclei and a
light cytoplasm (Fig. 4). No mitoses were present and the
Ki-67 proliferation index was low (2–3%). On the basis of
the typical immunohistological profile with strong
expression of HMB45 and without expression of S100,
the diagnosis of a PEComa was made.
The tumor was classified as unresectable in a nonaca-
demic peripheral hospital and the patient was referred to
our sarcoma center (SarKUM). On MRI, the neoplasm
showed no definite signs of local organ infiltration.
However, because of the presence of large areas of
necrosis and pathologically enlarged lymph nodes, in
combination with the size more than 5 cm, we suspected a
PEComa with malignant potential despite its histological
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homogenous and low proliferative nature. At our inter-
disciplinary sarcoma conference, the tumor was classified as
resectable only with mutilating surgery. Because of the size
and localization of the tumor next to the femoral and sciatic
nerve, and because of its contact to the sacrum, the only
possible surgical option for a complete resection was a
hemipelvectomy. The patient refused mutilating surgery;
thus, treatment with sirolimus was commenced. As in the
first case, we performed regular CT scans every 3 months.
The patient was closely monitored clinically by a local
oncologist, which included regular checks of plasma levels
of sirolimus. Plasma levels were found to be between 11
and 20 μg/l, and the therapy was tolerated without relevant
toxicity. To date, no interruption of the therapy has been
necessary. During follow-up, the scans showed a steady
decrease in tumor size, leading to a complete remission
(CR) after 1 year (Fig. 3b). The patient still refuses surgery
and is therefore being maintained on sirolimus therapy.
Discussion
Loss-of-function mutations in the tumor-suppressor
genes TSC1 or TSC2 seem to play an important role in
the pathomechanism of multiple benign as well as
malignant neoplasms, including TSC-associated tumors
such as angiofibromas and hamartomas as well as tumors
of the PEComa family.
In 70–90% of all patients with the TSC, a germline
mutation in the TSC2 gene or, less often the TSC1 gene,
can be observed. Nevertheless, most PEComas occur
sporadically and there is no known association between
TSC and malignant PEComa. TSC2 abberations are
commonly detected in sporadic PEComa [9]. Mutations
in the TSC1 and TSC2 genes result in hyperactivation of
the mTOR signaling pathway and subsequent abnorm-
alities in numerous cell processes.
Kenerson et al. [10] first described an aberrant mTOR
activity in angiomyolipomas, CCSTs, LAM, and also in
PEComas. As a specific and targeted therapy, the inhi-
bition of the mTOR complex 1 should be a promising
therapeutic approach. Sirolimus as a selective mTOR
complex 1 inhibitor is approved as an immunosuppressant
and used widely to prevent acute and chronic rejection
after organ transplantation [11].
As we initiated the therapy of our first patient, only two
relevant small series had been published, which indicated
Fig. 1
Hematoxylin and eosin staining of malignant perivascular epithelioid cell
tumor (patient 1).
Fig. 2
(a) Computed tomography (CT) image at baseline shows the maximal
size of the main lesion in the right pelvis. (b) CT image after 6 months of
treatment showing a significant decrease in size, consistent with a
partial remission. (c) No residual mass or local recurrence after
resection and under maintenance therapy with sirolimus. Small amount
of fluid in the pelvis.
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a possible positive effect of sirolimus on patients with
tumors of the PEComa family.
Bissler and colleagues published a study of metastatic or
locally unresectable, TSC-associated angiomyolipomas in
2008 and showed a significant but nondurable regression
in tumor volume following therapy with sirolimus. In
patients with pulmonary lymphangioleiomyomatosis, he
showed a slightly improved lung function [7].
In 2010, the first successful case of treatment of extra-
renal malignant PEComa with the mTOR inhibitor sir-
olimus was published. Three patients were treated; one
near CR of a multifocal retroperitoneal disease was
observed [8].
Spurred by these promising results, we decided to treat
patients in a similar manner. On the basis of the rarity of
the disease, there are no current guidelines for treatment.
Usually, if possible, a complete resection is recom-
mended. For different reasons, resection was not an
option. The first patient had undergone several extensive
abdominal resections in the past, whereas for the second
patient, a complete resection meant a mutilating surgery.
The results of a successful maintenance therapy with
more than 2 years of progression-free survival and a near
CR of locally advanced disease with prevention of
mutilating surgery are analogous to the results of the early
case reports. To date, several small series have been
published, mostly with positive results [12]. Dickson et al.
[9] treated five malignant PEComas and achieved long
durable responses including two CR of four of the five
treated patients. Currently, the largest series of malignant
PEComas treated with sirolimus has been published by
Benson et al. [13]. Of seven evaluable patients treated
with sirolimus five showed partial remission, one showed
stable disease, and one showed progressive disease.
Only one report describes the administration of sirolimus
in a neoadjuvant setting. Bergamo and colleagues repor-
ted a successful neoadjuvant treatment of a localized
hepatic PEComa with subsequent resection, but without
maintenance therapy.
Our findings confirm the positive results of sirolimus for
the treatment of malignant PEComas either in the
neoadjuvant setting or as postsurgical maintenance ther-
apy. It has to be mentioned that sirolimus is not labeled
for the described use.
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